Multithread effectively and personalize outreach to convert deals faster
Elevate social presence and drive business growth from social media
Identify and prioritize high-intent leads, and improve sales effectiveness
Find and connect with ICP attendees, and improve event outcomes
Kyverna Therapeutics is a patient-centered, clinical-stage biopharmaceutical company focused on developing and delivering transformative cell therapies for autoimmune diseases. Leveraging its expertise in T-cell engineering, Kyverna is advancing a pipeline of novel, wholly-owned therapeutic candidates designed to address the underlying causes of these debilitating conditions. Their lead candidate, KYV-101, is an autologous, fully human CD19 CAR T-cell product candidate being investigated for lupus nephritis and other B cell-driven autoimmune diseases. Kyverna aims to provide new hope and improved outcomes for patients with limited treatment options.
The headquarters serves as the central hub for Kyverna's research and development, clinical operations, corporate strategy, and administrative functions.
The facility includes modern laboratory spaces for cell therapy research and development, along with collaborative office environments designed to foster innovation.
Kyverna fosters a science-driven, patient-focused, and collaborative work culture. Employees are passionate about advancing novel therapies and working together to tackle complex scientific challenges in autoimmune disease.
Its location in the Bay Area provides access to a rich talent pool, leading research institutions, and a strong network of collaborators and investors crucial for a biotech company.
While Kyverna's primary physical operations are in the United States (Emeryville, CA and Waltham, MA), its global presence is expanding through its clinical trial activities. The company conducts multinational clinical studies for its therapeutic candidates, involving sites and patients in various countries to ensure diverse patient populations and accelerate development timelines. They also engage with the global scientific and medical community through publications, presentations, and collaborations.
1250 45th Street, Suite 350
Emeryville
CA
USA
Address: Undisclosed specific address, but presence confirmed for R&D/Technical Operations
To leverage the extensive biotech talent, research institutions, and infrastructure available in the Greater Boston area, complementing the Bay Area operations.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Kyverna Therapeutics' leadership includes:
Kyverna Therapeutics has been backed by several prominent investors over the years, including:
Kyverna has significantly strengthened its executive team over the past 12-18 months, particularly leading up to and following its IPO, with key appointments in scientific, financial, and information leadership.
Discover the tools Kyverna Therapeutics uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Kyverna Therapeutics likely uses common corporate email formats. The most probable format is [first_initial][last]@[company_domain].com or [first].[last]@[company_domain].com.
[first_initial][last]@kyverna.com
Format
pjones@kyverna.com
Example
80%
Success rate
Kyverna Therapeutics Press Release • June 3, 2024
Kyverna announced the appointment of Puja Sapra, Ph.D., as its Chief Scientific Officer. Dr. Sapra brings over 20 years of experience in oncology and immunology research and development....more
Kyverna Therapeutics Press Release • May 20, 2024
Kyverna reported its Q1 2024 financial results, highlighting progress in its KYV-101 clinical program for lupus nephritis and other autoimmune diseases, and a strong cash position following its IPO....more
Kyverna Therapeutics Press Release • February 13, 2024
Kyverna announced the successful closing of its Initial Public Offering (IPO), raising approximately $366.9 million in gross proceeds. This funding will support the advancement of its cell therapy pipeline....more
Kyverna Therapeutics Press Release • January 3, 2024
Kyverna received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial of KYV-101 in patients with myasthenia gravis, expanding its clinical program....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Kyverna Therapeutics, are just a search away.